Skip to content
Screener

Pfizer PFE Other, net

Other, net at other companies

Eli Lilly logo
Eli LillyLLY
-$4M+87.1%
Johnson & Johnson logo
Johnson & JohnsonJNJ
-$588M-1,570%
Amgen logo
AmgenAMGN
-$120M-30.4%
AbbVie logo
AbbVieABBV
$2M-97.0%
Viatris logo
ViatrisVTRS
-$24.5M+46.0%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE

Other financials

Income statement

See full
Revenue$15.0B+2.6%
Gross profit$10.9B+0.6%
Net income-$248.0M-109%
EPS (diluted)-$0.04-108%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$149.33B+9.8%
Enterprise value$212B+9.2%
P/E16.8×
P/S2.3×+0.2×

Profitability

See full
Gross margin73.2%+1.1pp
Net margin15.7%
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromPaymentsForOtherFinancingActivities.

The source filing: Pfizer’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 7:03 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000078003-26-000054
(MILLIONS)Three Months Ended / March 29,2026Three Months Ended / March 30,2025
Payments on short-term borrowings(2,048)
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less(127)(386)
Cash dividends paid(2,445)(2,437)
Other financing activities, net(284)(356)
Net cash provided by/(used in) financing activities(2,856)(5,227)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents19(7)
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents563375
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period1,1971,107

Item 1.

FAQ

What is Pfizer's other, net?
Pfizer (PFE) reported other, net of -$284M in Q1 2026.
How has Pfizer's other, net changed year-over-year?
Pfizer's other, net increased by 20.2% year-over-year, from -$356M to -$284M.
What is the long-term trend for Pfizer's other, net?
Over 2 years (2023 to 2025), Pfizer's other, net has grown at a -14.8% compound annual growth rate (CAGR), from -$631M to -$458M.
What does other, net mean?
Includes miscellaneous cash flows related to financing activities that are not categorized as debt issuance, dividends, or share repurchases. This may include changes in non-controlling interests, debt issuance costs, or other unique financing-related transactions. It provides a comprehensive view of non-standard financing cash movements.

Ask your AI about Pfizer's other, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude